Adding the BCL2 inhibitor venetoclax to fulvestrant did not improve clinical benefit rates (CBR) or PFS in women with oestrogen receptor-positive, HER2-negative locally advanced breast cancer compared to fulvestrant alone, new research from Australia reveals. Presenting the findings from the phase II VERONICA trial at ASCO this week lead investigator Professor Geoffrey Lindeman from the ...
Prof Geoff Lindeman: Venetoclax plus fulvestrant in ER+/HER2- breast cancer
By Sunalie Silva
9 Jun 2021